Olaparib Rejection By NICE Inconsistent With Personalized Medicine Goals, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The British pharma company says NICE’s rejection of its PARP inhibitor “is inconsistent” with EMA’s goal to accelerate access of personalized medicines and the U.K. government’s ambitions for promoting targeted medicines. Meanwhile Roche, Novartis, Boehringer Ingelheim and Bayer get green lights for their latest therapies from the cost-effectiveness watchdog.
You may also be interested in...
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.